Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 2
2011 1
2012 3
2013 6
2014 7
2015 6
2016 8
2017 3
2018 8
2019 10
2020 11
2021 7
2022 10
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma.
Scionti F, Juli G, Rocca R, Polerà N, Nadai M, Grillone K, Caracciolo D, Riillo C, Altomare E, Ascrizzi S, Caparello B, Cerra M, Arbitrio M, Richter SN, Artese A, Alcaro S, Tagliaferri P, Tassone P, Di Martino MT. Scionti F, et al. Among authors: di martino mt. J Exp Clin Cancer Res. 2023 Mar 27;42(1):71. doi: 10.1186/s13046-023-02633-0. J Exp Clin Cancer Res. 2023. PMID: 36967378 Free PMC article.
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci B, Salvino A, Lopreiato M, Thunarf F, Cuomo O, Zito MC, De Fina MR, Brescia A, Gualtieri S, Riillo C, Manti F, Caracciolo D, Barbieri V, Di Paola ED, Di Francesco AE, Tagliaferri P. Tassone P, et al. Among authors: di martino mt. J Hematol Oncol. 2023 Jun 26;16(1):68. doi: 10.1186/s13045-023-01468-8. J Hematol Oncol. 2023. PMID: 37365583 Free PMC article. Clinical Trial.
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
Riillo C, Polerà N, Di Martino MT, Juli G, Hokanson CA, Odineca T, Signorelli S, Grillone K, Ascrizzi S, Mancuso A, Staropoli N, Caparello B, Cerra M, Nisticò G, Tagliaferri P, Crea R, Caracciolo D, Tassone P. Riillo C, et al. Among authors: di martino mt. J Transl Med. 2023 May 4;21(1):301. doi: 10.1186/s12967-023-04101-x. J Transl Med. 2023. PMID: 37143061 Free PMC article.
The potential role of miRNAs in multiple myeloma therapy.
Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: di martino mt. Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Expert Rev Hematol. 2018. PMID: 30148649 Review.
Mir-34: a new weapon against cancer?
Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. Misso G, et al. Among authors: di martino mt. Mol Ther Nucleic Acids. 2014 Sep 23;3(9):e194. doi: 10.1038/mtna.2014.47. Mol Ther Nucleic Acids. 2014. PMID: 25247240 Free PMC article. Review.
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D, Polerà N, Belmonte B, Conforti F, Signorelli S, Gulino A, Staropoli N, Tuccillo FM, Bonelli P, Juli G, Grillone K, Ascrizzi S, Cirillo M, Migale L, Ballerini A, Pelizon C, Di Martino MT, Tagliaferri P, Riillo C, Tassone P. Caracciolo D, et al. Among authors: di martino mt. Br J Haematol. 2024 Feb;204(2):555-560. doi: 10.1111/bjh.19183. Epub 2023 Nov 14. Br J Haematol. 2024. PMID: 37963444
Mir-221/222 are promising targets for innovative anticancer therapy.
Di Martino MT, Rossi M, Caracciolo D, Gullà A, Tagliaferri P, Tassone P. Di Martino MT, et al. Expert Opin Ther Targets. 2016 Sep;20(9):1099-108. doi: 10.1517/14728222.2016.1164693. Epub 2016 Mar 21. Expert Opin Ther Targets. 2016. PMID: 26959615 Review.
87 results